Fortis Bank	R. Verhoef	BUY (27 Mar 2008)
Goldman Sachs	S. McGarry	HOLD (20 Nov 2007)
ING	M. Clarck	HOLD (23 Jun 2008)
Kempen & Co.	O. Izeboud / S. Soni	BUY (18 Sep 2008)
Needham & Company	A. Carr	BUY (13 Feb 2007)
Petercam	J. van de Bossche	SELL (13 Oct 2005)
Rabo Securities	F. Smeets	BUY (14 Mar 2008)
RBS	M. Gündogan	HOLD (13 Aug 2008)
SNS Securities	M. Wijma	BUY (14 Mar 2006)
Standard & Poor's	A. Jain	BUY (6 May 2008)
Theodoor Gilissen	T. Muller	BUY (22 Sep 2006)

Note: Crucell is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Crucell's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Crucell or its management. Crucell does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
	Crucell - A Star is Rising (October 14, 2005)
Note: This report has been prepared by Van Leeuwenhoeck Research based upon information provided by Crucell N.V. and publicly available sources. In addition, Van Leeuwenhoeck Research has published this report on request of Crucell and has been reimbursed for its services. www.vanleeuwenhoeck.com
	Quarterly Update (May 10, 2005)
	Quarterly Update (January 25, 2005)
	Quarterly Update (November 8, 2004)
	Quarterly Update (July 16, 2004)
	Crucell: Developing Biopharmaceuticals for Infectious Diseases

Note: This report has been prepared by Crucell N.V. (the “Company”) with the assistance of Crystal Research Associates, LLC based upon information provided by the Company. Crystal Research Associates has assimilated this content from publicly available information. In addition, Crystal Research Associates has been compensated in cash for its services.